Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;332(18):1574-1575.
doi: 10.1001/jama.2024.16984.

Preexposure Prophylaxis (PrEP) for HIV

Matthew A Spinelli  1 , Kenneth Ngure  2 , Monica Gandhi  1
Affiliations

Preexposure Prophylaxis (PrEP) for HIV

Matthew A Spinelli et al. JAMA. .
No abstract available

Plain language summary

This JAMA Insights discusses the expanding PrEP options for preventing HIV, including the considerations for initiation and follow-up and implementation challenges of these medications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The authors were funded by National Institute of Allergy and Infectious Diseases/National Institutes of Health grant 2R01AI143340 during the conduct of the study.

References

    1. Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. Published online July 24, 2024. doi:10.1056/NEJMoa2407001 - DOI - PubMed
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587–2599. doi:10.1056/NEJMoa1011205 - DOI - PMC - PubMed
    1. Marrazzo J, Tao L, Becker M, et al. HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women. JAMA. 2024;331(11):930–937. doi:10.1001/jama.2024.0464 - DOI - PMC - PubMed
    1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–2090. doi:10.1016/S0140-6736(13)61127-7 - DOI - PubMed
    1. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–254. doi:10.1016/S0140-6736(20)31065-5 - DOI - PMC - PubMed